XFOR — X4 PHARMACEUTICALS INC

Ownership history in Stonepine Capital Management, LLC  ·  2 quarters on record

This page tracks every 13F SEC filing in which Stonepine Capital Management, LLC reported a position in X4 PHARMACEUTICALS INC (XFOR). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
2.94% (2025 Q3)
Avg. % of fund
2.34%
First filed
2025 Q3
Last filed
2025 Q4
Quarters held
2
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 593,573 -462,765 -43.8% 1.73% $2.4M $4.00
2025 Q3 INITIATED 1,056,338 — — 2.94% $3.61B $3.42
% of Fund (quarterly)    XFOR price (monthly, adj. close)

Other funds also holding XFOR

As of 2025 Q4 — sorted by position size

Saturn V Capital Management LP 3Y 4.26% Rosalind Advisors, Inc. 3.66% Bain Capital Life Sciences Investors, LLC 3Y 7Y 2.44% CAXTON CORP 3Y 7Y 1.45% Samsara BioCapital, LLC 3Y 7Y 0.81% STEMPOINT CAPITAL LP 0.62% PERCEPTIVE ADVISORS LLC 3Y 7Y 0.45% BRAIDWELL LP 3Y 0.43% Deep Track Capital, LP 3Y 0.36% Nantahala Capital Management, LLC 3Y 7Y 0.32%
← Back to Stonepine Capital Management, LLC Holdings